Orphazyme AS (CHIX:ORPHAC) Total Equity : kr78.21 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Total Equity?

Orphazyme AS's total equity for the quarter that ended in Jun. 2022 was kr78.21 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Orphazyme AS Total Equity Historical Data

The historical data trend for Orphazyme AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Total Equity Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Equity

Get a 7-Day Free Trial

615.70

388.25

52.97

620.53

9.34

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Total Equity	Get a 7-Day Free Trial									506.14	620.53	166.76	9.34	78.21

Orphazyme AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Orphazyme AS's Total Equity for the fiscal year that ended in Dec. 2021 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2021 )	-	Total Liabilities(Q: Dec. 2021 )
	=	173.229	-	163.89
	=	9.34

Orphazyme AS's Total Equity for the quarter that ended in Jun. 2022 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2022 )	-	Total Liabilities(Q: Jun. 2022 )
	=	93.589	-	15.384
	=	78.21

Orphazyme AS Total Equity Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines